TY - JOUR
T1 - Tamoxifen resistance trumped and oral selective estrogen receptor degraders arrive
AU - Jordan, V. Craig
N1 - Publisher Copyright:
© 2018 American Association for Cancer Research.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Predictive tests, to refine the estrogen receptor assay, for the adjuvant treatment of breast cancer with tamoxifen and oral selective estrogen receptor degraders (SERD) are required. A splice variant of the corepressor NCOR2, BQ2313636.1 predicts tamoxifen resistance to adjuvant tamoxifen and AZ9496, the first oral SERD, completes phase I studies.
AB - Predictive tests, to refine the estrogen receptor assay, for the adjuvant treatment of breast cancer with tamoxifen and oral selective estrogen receptor degraders (SERD) are required. A splice variant of the corepressor NCOR2, BQ2313636.1 predicts tamoxifen resistance to adjuvant tamoxifen and AZ9496, the first oral SERD, completes phase I studies.
UR - http://www.scopus.com/inward/record.url?scp=85050997823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050997823&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-0759
DO - 10.1158/1078-0432.CCR-18-0759
M3 - Article
C2 - 29674510
AN - SCOPUS:85050997823
SN - 1078-0432
VL - 24
SP - 3480
EP - 3482
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 15
ER -